Drug Profile
CTV 05
Alternative Names: CTV-05; LACTIN-V; Lactobacillus crispatus CTV-05Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator GyneLogix
- Developer National Institute of Allergy and Infectious Diseases; Osel Inc; The Fertility Clinic, Skive; University of Washington
- Class Probiotics
- Mechanism of Action Bacteria replacements; Vaginal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Urinary tract infections
- Phase II Bacterial vaginosis
Most Recent Events
- 16 Aug 2023 The Fertility Clinic, Skive completes the phase II trial inBacterial vaginosis in Denmark (Vaginal) (NCT05166746) (EudraCT2016-002385-31)
- 10 May 2021 Phase-II clinical trials in Bacterial vaginosis in South Africa (Vaginal) (NCT05022212)
- 03 Feb 2021 Osel enters into a clinical trial licensing agreement with Danish Research Consortia (comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark) for LACTIN-V for Bacterial vaginosis